Efflux Pharma Contact
Clinical-stage biotechnology · Oncology

We make cancer
treatments work

SCO-101 is a triple-acting add-on that restores the efficacy of established anti-cancer drugs. By switching off the very mechanisms tumours use to become drug resistant

Explore the science View the pipeline
Phase IIa
Lead programme CORIST in metastatic colorectal cancer
3 targets
One molecule, three resistance mechanisms
375+
Peer-reviewed papers behind the science
The problem

Drug resistance is the
last line of cancer's defence

Cancer drug resistance continues to be the major limiting factor to achieving cure for cancer patients. Tumours either carry resistant cells from the start, or acquire defences over the course of treatment — until the drugs that once worked, no longer do.

How resistance develops
Pipeline

One compound, a broadening portfolio

SCO-101 is designed as a combination partner pairing with chemotherapy, endocrine treatment and other anti-cancer agents across a widening set of indications.

See the CORIST programme
Mechanism of action

A triple-acting mode of action

SCO-101 inhibits three distinct targets that tumours rely on to resist treatment — making well-established therapies effective.

01 / Efflux pump
ABCG2
Drug efflux pump · stem-cell marker
Extracellular Cytoplasm

SCO-101 inhibits the ABCG2 efflux pump, trapping cytotoxic chemotherapy inside the cancer cell.

More drug inside → more cancer-cell death
02 / Enzyme
UGT1A1
Drug-metabolising liver enzyme

Inhibiting UGT1A1 slows the clearance of SN-38, the active metabolite of irinotecan.

Longer SN-38 exposure & half-life
03 / Kinase
SRPK1
Serine / arginine-rich kinase
P

SRPK1 inhibition targets a known driver of endocrine-treatment - and taxane resistance in cancer.

Re-sensitises endocrine-resistant tumours
Read the full science
Founder · Scientific lead
Leadership

Three decades of cancer-resistance science

Efflux Pharma is led by Nils Brünner, MD, DMSc — Professor Emeritus at the University of Copenhagen and co-founder of Scandion Oncology, where SCO-101 first entered pre-clinical and clinical development.

Nils brings 15 years of training in internal medicine and oncology, and more than 30 years of translational cancer research. A former Center Director of a Danish National Research Foundation centre focused on anti-cancer drug resistance, he has published over 375 scientific papers in the field.

More about the company

Partnering to bring SCO-101
to the patients who need it

Get in touch